SG11201700171VA - Signalling system - Google Patents
Signalling systemInfo
- Publication number
- SG11201700171VA SG11201700171VA SG11201700171VA SG11201700171VA SG11201700171VA SG 11201700171V A SG11201700171V A SG 11201700171VA SG 11201700171V A SG11201700171V A SG 11201700171VA SG 11201700171V A SG11201700171V A SG 11201700171VA SG 11201700171V A SG11201700171V A SG 11201700171VA
- Authority
- SG
- Singapore
- Prior art keywords
- signalling system
- signalling
- Prior art date
Links
- 230000011664 signaling Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1415347.2A GB201415347D0 (en) | 2014-08-29 | 2014-08-29 | Signalling system |
| PCT/GB2015/052494 WO2016030691A1 (en) | 2014-08-29 | 2015-08-28 | Signalling system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201700171VA true SG11201700171VA (en) | 2017-02-27 |
Family
ID=51752358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201700171VA SG11201700171VA (en) | 2014-08-29 | 2015-08-28 | Signalling system |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10654927B2 (en) |
| EP (2) | EP3981417A1 (en) |
| JP (1) | JP6614619B2 (en) |
| KR (1) | KR102222615B1 (en) |
| CN (1) | CN106573989B (en) |
| AU (1) | AU2015308243B2 (en) |
| BR (1) | BR112017003906A2 (en) |
| CA (1) | CA2955668A1 (en) |
| CL (1) | CL2017000438A1 (en) |
| ES (1) | ES2910008T3 (en) |
| GB (1) | GB201415347D0 (en) |
| IL (1) | IL250101B (en) |
| MX (1) | MX2017000616A (en) |
| NZ (1) | NZ728674A (en) |
| RU (1) | RU2731638C2 (en) |
| SG (1) | SG11201700171VA (en) |
| WO (1) | WO2016030691A1 (en) |
| ZA (1) | ZA201700466B (en) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014117121A1 (en) | 2013-01-28 | 2014-07-31 | St. Jude Children's Research Hospital, Inc. | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| US20230021548A1 (en) | 2014-03-05 | 2023-01-26 | Autolus Limited | Methods |
| US11385233B2 (en) | 2015-03-05 | 2022-07-12 | Autolus Limited | Methods of depleting malignant T-cells |
| GB201403972D0 (en) | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| WO2015174928A1 (en) | 2014-05-15 | 2015-11-19 | National University Of Singapore | Modified natural killer cells and uses thereof |
| GB201501936D0 (en) | 2015-02-05 | 2015-03-25 | Ucl Business Plc | Signalling system |
| GB201504840D0 (en) | 2015-03-23 | 2015-05-06 | Ucl Business Plc | Chimeric antigen receptor |
| EP3288570A4 (en) * | 2015-04-29 | 2018-11-21 | Fred Hutchinson Cancer Research Center | Modified stem cells and uses thereof |
| CA2986254A1 (en) | 2015-05-18 | 2016-11-24 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| GB201602571D0 (en) * | 2016-02-12 | 2016-03-30 | Autolus Ltd | Signalling system |
| GB201602563D0 (en) * | 2016-02-12 | 2016-03-30 | Autolus Ltd | Signalling system |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| WO2018009923A1 (en) * | 2016-07-08 | 2018-01-11 | F1 Oncology, Inc. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| GB201610515D0 (en) * | 2016-06-16 | 2016-08-03 | Autolus Ltd | Cell |
| JP7109789B2 (en) | 2016-08-02 | 2022-08-01 | ティーシーアール２ セラピューティクス インク． | Compositions and methods for TCR reprogramming using fusion proteins |
| MX2019003899A (en) | 2016-10-07 | 2019-08-14 | Tcr2 Therapeutics Inc | Compositions and methods for t-cell receptors reprogramming using fusion proteins. |
| CN110114371A (en) | 2016-11-11 | 2019-08-09 | 奥托路斯有限公司 | Chimeric antigen receptor |
| CN110177803A (en) | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | For using fusion protein to carry out the composition and method that TCR is reprogramed |
| GB201621891D0 (en) * | 2016-12-21 | 2017-02-01 | Autolus Ltd | Transcription system |
| MX2019011570A (en) | 2017-03-27 | 2019-11-18 | Nat Univ Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells. |
| JP7256749B2 (en) | 2017-03-27 | 2023-04-12 | ナショナル ユニヴァーシティー オブ シンガポール | Truncated NKG2D chimeric receptor and its use in natural killer cell immunotherapy |
| US20200188434A1 (en) * | 2017-05-15 | 2020-06-18 | Autolus Limited | A cell comprising a chimeric antigen receptor (car) |
| GB201709203D0 (en) | 2017-06-09 | 2017-07-26 | Autolus Ltd | Antigen-binding domain |
| GB201709508D0 (en) * | 2017-06-15 | 2017-08-02 | Autolus Ltd | Chimeric antigen receptor |
| US20210130775A1 (en) * | 2017-08-02 | 2021-05-06 | Autolus Limited | Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed |
| CN107475276A (en) * | 2017-09-05 | 2017-12-15 | 深圳大学 | The T cell and its application that Chimeric antigen receptor and its expressing gene, the Chimeric antigen receptor of tetracycline regulation are modified |
| GB201717524D0 (en) | 2017-10-25 | 2017-12-06 | Autolus Ltd | Vectors |
| GB201805918D0 (en) * | 2018-04-10 | 2018-05-23 | Autolus Ltd | Cell |
| EP3774866A1 (en) | 2018-04-13 | 2021-02-17 | Ludwig Institute for Cancer Research Ltd | Heterodimeric inactivatable chimeric antigen receptors |
| GB201807693D0 (en) | 2018-05-11 | 2018-06-27 | Autolus Ltd | Cell |
| EP3794034A1 (en) | 2018-05-15 | 2021-03-24 | Autolus Limited | Chimeric antigen receptor |
| GB201813178D0 (en) | 2018-08-13 | 2018-09-26 | Autolus Ltd | Cell |
| JP7458382B2 (en) | 2018-09-27 | 2024-03-29 | オートラス リミテッド | Chimeric Antigen Receptor |
| GB201816839D0 (en) * | 2018-10-16 | 2018-11-28 | Glaxosmithkline Ip Dev Ltd | Novel control switch |
| WO2020180882A1 (en) | 2019-03-05 | 2020-09-10 | Nkarta, Inc. | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| GB201903237D0 (en) | 2019-03-08 | 2019-04-24 | Autolus Ltd | Method |
| US20220145325A1 (en) | 2019-03-08 | 2022-05-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| GB201906202D0 (en) | 2019-05-02 | 2019-06-19 | Autolus Ltd | Cell |
| GB201910185D0 (en) | 2019-07-16 | 2019-08-28 | Autolus Ltd | Method |
| WO2021009510A1 (en) | 2019-07-16 | 2021-01-21 | Autolus Limited | Method for preconditioning a subject who is about to receive a t-cell therapy |
| GB201913258D0 (en) | 2019-09-13 | 2019-10-30 | Autolus Ltd | Antigen-binding domain |
| GB201919017D0 (en) | 2019-12-20 | 2020-02-05 | Autolus Ltd | Cell |
| GB201919019D0 (en) | 2019-12-20 | 2020-02-05 | Autolus Ltd | Antigen-binding domain |
| GB202005216D0 (en) | 2020-04-08 | 2020-05-20 | Autolus Ltd | Cell |
| US20230133554A1 (en) | 2020-04-09 | 2023-05-04 | Autolus Limited | Molecule |
| GB202101491D0 (en) | 2021-02-03 | 2021-03-17 | Autolus Ltd | Molecule |
| GB202007044D0 (en) | 2020-05-13 | 2020-06-24 | Autolus Ltd | Method |
| GB202017343D0 (en) | 2020-11-02 | 2020-12-16 | Autolus Ltd | Cell |
| GB202104030D0 (en) | 2021-03-23 | 2021-05-05 | Autolus Ltd | Signalling system |
| GB202115329D0 (en) | 2021-10-25 | 2021-12-08 | Autolus Ltd | Chimeric cytokine receptor |
| GB202209920D0 (en) | 2022-07-06 | 2022-08-17 | Autolus Ltd | Cell |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011215685B2 (en) | 2010-02-12 | 2015-08-20 | Oncomed Pharmaceuticals, Inc. | Methods for identifying and isolating cells expressing a polypeptide |
| CN110423282B (en) * | 2013-02-15 | 2023-09-08 | 加利福尼亚大学董事会 | Chimeric antigen receptor and methods of use thereof |
| CN109897100A (en) | 2013-05-13 | 2019-06-18 | 瑟勒提斯公司 | CD19 specific chimeric antigen receptor and application thereof |
| JP6433498B2 (en) * | 2013-11-21 | 2018-12-05 | ユーシーエル ビジネス ピーエルシー | cell |
| EP3087101A4 (en) | 2013-12-20 | 2017-12-06 | Novartis AG | Regulatable chimeric antigen receptor |
| EP3811970A1 (en) | 2014-03-15 | 2021-04-28 | Novartis AG | Regulatable chimeric antigen receptor |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| US9791929B2 (en) * | 2014-10-31 | 2017-10-17 | Elwha Llc | Tactile control system |
| SG11201704084VA (en) * | 2014-12-24 | 2017-06-29 | Ucl Business Plc | Cell |
| GB201501936D0 (en) | 2015-02-05 | 2015-03-25 | Ucl Business Plc | Signalling system |
| GB201504840D0 (en) | 2015-03-23 | 2015-05-06 | Ucl Business Plc | Chimeric antigen receptor |
| MY196175A (en) * | 2016-01-11 | 2023-03-20 | Univ Leland Stanford Junior | Chimeric Proteins And Methods Of Regulating Gene Expression |
| GB201602563D0 (en) | 2016-02-12 | 2016-03-30 | Autolus Ltd | Signalling system |
| GB201602571D0 (en) | 2016-02-12 | 2016-03-30 | Autolus Ltd | Signalling system |
| GB201610515D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Cell |
-
2014
- 2014-08-29 GB GBGB1415347.2A patent/GB201415347D0/en not_active Ceased
-
2015
- 2015-08-28 CA CA2955668A patent/CA2955668A1/en not_active Abandoned
- 2015-08-28 CN CN201580045056.1A patent/CN106573989B/en active Active
- 2015-08-28 BR BR112017003906-0A patent/BR112017003906A2/en not_active IP Right Cessation
- 2015-08-28 AU AU2015308243A patent/AU2015308243B2/en not_active Ceased
- 2015-08-28 JP JP2017511182A patent/JP6614619B2/en active Active
- 2015-08-28 RU RU2017105515A patent/RU2731638C2/en active
- 2015-08-28 SG SG11201700171VA patent/SG11201700171VA/en unknown
- 2015-08-28 EP EP21193028.4A patent/EP3981417A1/en active Pending
- 2015-08-28 MX MX2017000616A patent/MX2017000616A/en active IP Right Grant
- 2015-08-28 ES ES15757558T patent/ES2910008T3/en active Active
- 2015-08-28 KR KR1020177007191A patent/KR102222615B1/en active IP Right Grant
- 2015-08-28 NZ NZ728674A patent/NZ728674A/en not_active IP Right Cessation
- 2015-08-28 US US15/506,383 patent/US10654927B2/en active Active
- 2015-08-28 WO PCT/GB2015/052494 patent/WO2016030691A1/en active Application Filing
- 2015-08-28 EP EP15757558.0A patent/EP3185875B1/en active Active
-
2017
- 2017-01-15 IL IL250101A patent/IL250101B/en active IP Right Grant
- 2017-01-19 ZA ZA2017/00466A patent/ZA201700466B/en unknown
- 2017-02-23 CL CL2017000438A patent/CL2017000438A1/en unknown
-
2020
- 2020-04-14 US US16/848,717 patent/US20210032332A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20210032332A1 (en) | 2021-02-04 |
| RU2017105515A3 (en) | 2018-10-01 |
| US20170260269A1 (en) | 2017-09-14 |
| CN106573989A (en) | 2017-04-19 |
| US10654927B2 (en) | 2020-05-19 |
| RU2017105515A (en) | 2018-10-01 |
| ES2910008T3 (en) | 2022-05-11 |
| IL250101A0 (en) | 2017-03-30 |
| EP3981417A1 (en) | 2022-04-13 |
| MX2017000616A (en) | 2017-07-20 |
| CL2017000438A1 (en) | 2017-08-18 |
| AU2015308243A1 (en) | 2017-02-23 |
| AU2015308243B2 (en) | 2020-01-30 |
| RU2731638C2 (en) | 2020-09-07 |
| JP2017526361A (en) | 2017-09-14 |
| WO2016030691A1 (en) | 2016-03-03 |
| EP3185875B1 (en) | 2022-01-05 |
| EP3185875A1 (en) | 2017-07-05 |
| KR102222615B1 (en) | 2021-03-05 |
| GB201415347D0 (en) | 2014-10-15 |
| NZ728674A (en) | 2020-05-29 |
| KR20170045258A (en) | 2017-04-26 |
| CN106573989B (en) | 2022-02-01 |
| BR112017003906A2 (en) | 2018-02-27 |
| IL250101B (en) | 2020-11-30 |
| JP6614619B2 (en) | 2019-12-04 |
| CA2955668A1 (en) | 2016-03-03 |
| ZA201700466B (en) | 2018-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201700466B (en) | Signalling system | |
| IL251719B (en) | Cybersecurity system | |
| GB201405845D0 (en) | Signalling system | |
| GB201501936D0 (en) | Signalling system | |
| GB201417453D0 (en) | Location system | |
| GB201421498D0 (en) | Ventalation System | |
| GB201403908D0 (en) | Communicatioon system | |
| GB201602563D0 (en) | Signalling system | |
| GB201602571D0 (en) | Signalling system | |
| EP3254897C0 (en) | Signalling system | |
| GB201411097D0 (en) | 329 - octo-lateral system | |
| GB201405654D0 (en) | Mounting system | |
| PL3087213T3 (en) | Continuous system | |
| GB201413985D0 (en) | Improved ACAES system | |
| GB2530120B (en) | Alarm system | |
| GB201620472D0 (en) | Signalling device | |
| SG10201500603SA (en) | Monitoring-And-Control System | |
| GB201602569D0 (en) | Signalling system | |
| GB201417116D0 (en) | Telescopic-lateral system | |
| GB201417063D0 (en) | System | |
| HK1197527A2 (en) | Positioing system | |
| GB201413642D0 (en) | System | |
| GB201411684D0 (en) | Detecttion system | |
| GB201411329D0 (en) | Octopus-lateral system | |
| GB201409787D0 (en) | System |